Promotion
Jobs
Asset Processing
Content
New Arrival Informations
-
Sep 21, 2010
[Japan] -
Sep 21, 2010
[India] -
Sep 10, 2010
[People's Republic of China] -
Apr 26, 2010
[Japan] -
Apr 26, 2010
[Japan]
Company Profile: IMMUTECH PHARMACEUTICALS LTD
| Company Name | IMMUTECH PHARMACEUTICALS LTD |
|---|---|
| Country | People's Republic of Bangladesh |
| Zip Code | 1216 |
| Address | Hyperion Heritage,plot # 14-15, Block- 2F, Eastern Housing Ltd,Pallabi,Dhaka.Bangladesh. |
| Telephone Number | It can see after login. |
| Fax Number | It can see after login. |
| URL | It can see after login. |
| Mail Address | It can see after login. |
| Representative | Md.Hammad Ali Talukder |
| PR |
Focus on Results... According to the World Health Organization, infectious diseases collectively represent the most common cause of death worldwide. In the past twenty years, however, very few new treatments have been developed for infectious diseases. Immtech Pharmaceuticals, Inc. (NYSE Alternext: IMM) aims to realize significant returns by developing safe and effective cures for infectious diseases that affect the global community. The Company is also positioned to pursue a range of commercial opportunities in China and other emerging global markets for healthcare products and services. History Focus on Infectious Diseases Immtech Pharmaceuticals is dedicated to the discovery and development of therapies to treat infectious diseases that affect the global community. The company is traded on the American Stock Exchange (NYSE Alternext: IMM). Exclusivity Immtech Pharmaceuticals holds an exclusive, worldwide license to develop and commercialize a broad platform of chemical compounds that have demonstrated the ability to act against a number of infectious diseases. Immtech’s unique drug discovery model includes multiple research efforts conducted by a Scientific Consortium that includes world-renowned scientists who advance the Company’s search for drug candidates by screening multiple compounds for activity against specific microorganisms. We have exclusive license to a family of compounds covered by patents issued worldwide. Immtech is working on promising pre-clinical drug discovery programs to identify new treatments for a range of infectious diseases including hepatitis C (HCV), fungal diseases and multi-drug resistant strains of bacterial infections. Read more about our exclusive technology platform. Prospects Global Commercial Opportunities We look for opportunities to develop strategic partnerships and alliances. Partnership with other pharmaceutical companies and international health organizations could provide an established distribution presence for Immtech in developed and developing markets as well as complementary expertise or access to a partner drug. Our ongoing drug discovery activities include programs in hepatitis C (HCV), fungal diseases and multi-drug resistant strains of bacterial infections. We are open to the possibility of collaborative development, licensing or distribution partnerships in these target indications. Immtech’s extensive experience in drug development, manufacturing, and regulatory procedures in China represents a significant resource for both our own development programs and for companies seeking to pursue commercial opportunities in this fast growing market. |
Makers-IN会員情報
Register to the Makers-IN (free of charge) for the inquiry. Free member
